One Antibody Trial Is Halted, While Others Continue
An ongoing trial of the antibody bamlanivimab—administered with remdesivir, an antiviral medication—on hospitalized COVID-19 patients has been halted by bamlanivimab’s manufacturer Eli Lilly. The decision was made to stop the trial after…